Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated literature review

Isabella R. Plumptrea Imperial College Healthcare NHS Trust, London, UK

Jordan T. Saidb Department of Dermatology, Brigham and Women’s Hospital, Boston, MA, USA;c Harvard Medical School, Boston, MA, USA

https://orcid.org/0000-0002-0357-6916

Tiffany Sunb Department of Dermatology, Brigham and Women’s Hospital, Boston, MA, USA;d Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Cecilia Laroccab Department of Dermatology, Brigham and Women’s Hospital, Boston, MA, USA;c Harvard Medical School, Boston, MA, USA;d Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Cesar A. Virgenb Department of Dermatology, Brigham and Women’s Hospital, Boston, MA, USA;c Harvard Medical School, Boston, MA, USA;d Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Thomas S. Kupperb Department of Dermatology, Brigham and Women’s Hospital, Boston, MA, USA;c Harvard Medical School, Boston, MA, USA;d Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

David C. Fisherc Harvard Medical School, Boston, MA, USA;d Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Philip M. Devlinc Harvard Medical School, Boston, MA, USA;d Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;e Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, MA, USA

Christopher P. Elcoc Harvard Medical School, Boston, MA, USA;f Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

Johanna Sheu Songb Department of Dermatology, Brigham and Women’s Hospital, Boston, MA, USA;d Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Nicole R. LeBoeufb Department of Dermatology, Brigham and Women’s Hospital, Boston, MA, USA;c Harvard Medical School, Boston, MA, USA;d Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USACorrespondence[email protected]

show all

Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated literature review

GLAL-2022-0155-File005.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated literature review

GLAL-2022-0155-File005.docx

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date